Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Subcutaneous Vs IV Atezolizumab Demonstrates Non-Inferior Pharmacokinetics in Advanced NSCLC
August 3rd 2022Results from the phase 3 IMscin001 trial indicated that atezolizumab given subcutaneously vs intravenously yielded non-inferior pharmacokinetics for patients with immunotherapy-naïve locally advanced or metastatic non–small cell lung cancer.
FDA Accepts BLA And Grants Priority Review to Omidubicel in Hematologic Malignancies
August 2nd 2022Based on results from a phase 3 trial, the FDA has accepted a biologics license application for and granted priority review to omidubicel for those with hematologic malignancies who require allogenic hematopoietic stem cell transplant.
Addition of Elotuzumab to KRd Yields Promising Responses in Newly Diagnosed Multiple Myeloma
August 1st 2022Results from a phase 2 study indicated that adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone with a minimal residual disease–adapted design boosted responses for those with newly diagnosed multiple myeloma.
Radiotherapy Induced Taste Dysfunction During and 3 Months After Treatment in Head and Neck Cancer
August 1st 2022Treatment with radiotherapy for head and neck cancer resulted in taste dysfunction during treatment and 3 months thereafter, although reduction in oral cavity intensity-modulated radiotherapy dose may result in early taste function recovery.
Findings Support Liso-Cel in the Second-Line for Large B-Cell Lymphoma Not Intended for HSCT
July 28th 2022Findings from the phase 2 TRANSCEND-PILOT-017006 supported the use of lisocabtagene maraleucel as a second-line treatment for patients with large B-cell lymphoma who were not able to or didn’t want to receive hematopoietic stem cell transplant.
Enfortumab Vedotin Plus Pembrolizumab Yield Promising Results in Advanced Urothelial Carcinoma
July 26th 2022Results from cohort K of the phase 1b/2 KEYNOTE-869 trial showed improved responses for patients with advanced or metastatic urothelial carcinoma when treated with enfortumab vedotin-efjv plus pembrolizumab.
Medicaid Associated With Reduction in Racial/Ethnic Disparities in De Novo Stage IV Breast Cancer
July 19th 2022Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.
Atezolizumab Plus Bevacizumab Induces Promising Clinical Responses in Neuroendocrine Tumors
July 19th 2022Patients with pancreatic and extrapancreatic neuroendocrine tumors treated with atezolizumab plus bevacizumab experienced consistent clinical responses and a progression-free survival consistent with other therapies.
Cabozantinib Combination Yields Improvement in PFS for Advanced RCC
July 12th 2022The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.
Apatinib Plus Pegylated Liposomal Doxorubicin Yields Significant Efficacy in Advanced Ovarian Cancer
July 11th 2022Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.